415 related articles for article (PubMed ID: 21468005)
21. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.
Truxova I; Pokorna K; Kloudova K; Partlova S; Spisek R; Fucikova J
Immunol Lett; 2014 Jul; 160(1):39-49. PubMed ID: 24726860
[TBL] [Abstract][Full Text] [Related]
22. The Journey of
Goyvaerts C; Breckpot K
Front Immunol; 2018; 9():2052. PubMed ID: 30254636
[TBL] [Abstract][Full Text] [Related]
23. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
[TBL] [Abstract][Full Text] [Related]
24. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
Bhargava A; Mishra D; Banerjee S; Mishra PK
Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
[TBL] [Abstract][Full Text] [Related]
27. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
28. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang HY; Wang RF
Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
[TBL] [Abstract][Full Text] [Related]
29. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
30. Dendritic-tumor fusion cells in cancer immunotherapy.
Takakura K; Kajihara M; Ito Z; Ohkusa T; Gong J; Koido S
Discov Med; 2015 Mar; 19(104):169-74. PubMed ID: 25828520
[TBL] [Abstract][Full Text] [Related]
31. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
[TBL] [Abstract][Full Text] [Related]
32. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.
Chen YZ; Yao XL; Tabata Y; Nakagawa S; Gao JQ
Clin Dev Immunol; 2010; 2010():565643. PubMed ID: 21197274
[TBL] [Abstract][Full Text] [Related]
33. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
34. Personalized dendritic cell-based tumor immunotherapy.
Janikashvili N; Larmonier N; Katsanis E
Immunotherapy; 2010 Jan; 2(1):57-68. PubMed ID: 20161666
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
37. Genetically modified dendritic cells for cancer immunotherapy.
Ribas A
Curr Gene Ther; 2005 Dec; 5(6):619-28. PubMed ID: 16457651
[TBL] [Abstract][Full Text] [Related]
38. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
39. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
40. DNA and RNA modified dendritic cell vaccines.
Morse MA; Lyerly HK
World J Surg; 2002 Jul; 26(7):819-25. PubMed ID: 11948364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
